In a report released today, Michael Matson from Needham assigned a Buy rating to Cardiovascular Systems (CSII), with a price target of $44.00. The company’s shares closed last Thursday at $37.43.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 9.3% and a 60.7% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Merit Medical Systems.
Cardiovascular Systems has an analyst consensus of Strong Buy, with a price target consensus of $44.00.
See today’s analyst top recommended stocks >>
Based on Cardiovascular Systems’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $42.55 million and GAAP net loss of $15.17 million. In comparison, last year the company earned revenue of $68.23 million and had a net profit of $1.47 million.
Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CSII in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. Its products are catheter-based platforms capable of treating a range of vessel sizes and plaque types. The company was founded in 2000 and is headquartered in St. Paul, MN.
